Latest Content

FDA Grants Fast Track Designation to R289 in Lower-Risk MDS

December 5th 2024, 2:00pm

By Alex Biese

Article

The novel treatment is being evaluated for patients with previously treated transfusion-dependent lower-risk myelodysplastic syndrome.

FDA OKs Imfinzi for Limited-Stage Small Cell Lung Cancer

December 5th 2024, 12:41am

By Darlene Dobkowski, MA

Article

Imfinzi was approved by the FDA for the treatment of adults with limited-stage small cell lung cancer without disease progression after chemotherapy and radiation.

FDA Approves Bizengri for Some with NSCLC, Pancreatic Adenocarcinoma

December 4th 2024, 9:05pm

By Alex Biese

Article

The FDA has approved the first systemic therapy for patients with NSCLC or pancreatic adenocarcinoma with an NRG1 gene fusion.

Expert Explains Lymphoma After Dave Coulier's Diagnosis

December 4th 2024, 8:00pm

By Alex Biese

Article

An expert from the CURE® advisory board explains the likely treatability of Dave Coulier’s non-Hodgkin lymphoma.

Time, My Most Precious Gift After Breast Cancer

December 4th 2024, 6:00pm

By Bonnie Annis

Article

I’ve learned to live in the present by avoiding clocks, a necessary change in my life after having breast cancer.

Partial Nephrectomy May Improve Survival in cT1a Renal Cell Carcinoma

December 4th 2024, 4:00pm

By Spencer Feldman

Article

Partial nephrectomy showed similar overall and cancer-specific survival rates to radiofrequency ablation in patients with cT1a RCC.

Phase 3 Study for Advanced Pancreatic Cancer Meets Survival Goal

December 4th 2024, 2:00pm

By Ashley Chan

Article

Patients with locally advanced pancreatic cancer demonstrated a two-month difference in survival with tumor-treating fields versus chemotherapy.

FDA Grants Breakthrough Therapy Designation to Sac-TMT for Some with NSCLC

December 3rd 2024, 10:00pm

By Alex Biese

Article

The FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for patients with advanced or metastatic nonsquamous NSCLC with EGFR mutations.

Nemvaleukin Shows Manageable Safety Profile in Advanced Solid Tumors

December 3rd 2024, 8:00pm

By Ashley Chan

Article

In patients with advanced solid tumors, treatment with nemvaleukin with or without Keytruda demonstrated antitumor activity and tolerability.

Loss and Life Have Given Me a Wealth of Gratitude After Cancer

December 3rd 2024, 6:00pm

By Carla Deschamps

Article

When my grandmother passed away one Thanksgiving after my colon cancer diagnosis, I realized how grateful I am for her life and my own as a survivor.

How a Singer-Songwriter’s Cancer History Can Be Heard in Her Music

December 3rd 2024, 4:00pm

By Alex Biese

Article

Singer-songwriter Danielia Cotton, a thyroid cancer survivor and marathon runner shared how her experiences impact her art.

Blenrep Combo Accepted for FDA Review in R/R Multiple Myeloma

December 3rd 2024, 2:00pm

By Spencer Feldman

Article

The FDA has accepted a biologics license application for Blenrep plus bortezomib or pomalidomide for patients with relapsed or refractory multiple myeloma.

Tiragolumab Plus Tecentriq Misses Survival Endpoint for Lung Cancer Subset

December 2nd 2024, 10:00pm

By Darlene Dobkowski, MA

Article

The primary endpoint of overall survival was missed in the SKYSCRAPER-01 study assessing tiragolumab plus Tecentriq in some patients with non-small cell lung cancer.

‘The Future Is Bright’ for R/R CLL Treatment Landscape

December 2nd 2024, 8:00pm

By Ashley Chan

Video

Current treatments for patients with relapsed or refractory chronic lymphocytic leukemia have shown better outcomes than published data, an expert said.

My Gratitude for Brighter Moments as a New Mom With Cancer

December 2nd 2024, 6:00pm

By Angela Patterson

Article

Reflecting on my first diagnosis of breast cancer at 36 weeks pregnant has made me feel grateful for the positive moments during that dark time.